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The Food and Drug Administration (FDA), the agency of the federal gov-
ernment responsible for protecting the public against impure and unsafe
drugs, classifies as prescription drugs all drugs which cannot be made com-
pletely safe due to their nature or to the current state of pharmacology.'
When accompanied by an appropriate manufacturer warning, prescription
drugs are considered to be unavoidably unsafe but not unreasonably
dangerous.
2
The traditional source of warnings about the dangers and possible side-
effects of prescription drugs has been the prescribing physician. Prescription
drug manufacturers have had no legal duty to inform consumers directly
about their products because the prescribing physician has acted as a learned
intermediary between the manufacturer and the consumer.3 The duty to
1. The Federal Food, Drug, and Cosmetic Act (codified as amended in scattered sections
of title 21 U.S.C.) defines a prescription drug as
[a] drug intended for use by man which . . . (B) because of its toxicity or other
potentiality for harmful effect . . . is not safe for use except under the supervision of
a practitioner licensed by law to administer such drug ....
2. Unavoidably unsafe products are discussed in RESTATEMENT (SECOND) OF TORTS
§ 402A (1965). Comment k states in relevant part:
There are some products which, in the present state of human knowledge, are
quite incapable of being made safe for their intended and ordinary use. These are
especially common in the field of drugs. . . . Such a product, properly prepared,
and accompanied by proper directions and warnings, is not defective, nor is it unrea-
sonably dangerous. . . . The seller of such products, again with the qualification
that they are properly prepared and marketed, and proper warning is given, where
the situation calls for it, is not to be held to strict liability for unfortunate conse-
quences attending their use, merely because he has undertaken to supply the public
with an apparently useful and desirable product, attended with a known but appar-
ently reasonable risk.
RESTATEMENT (SECOND) OF TORTS § 402A comment k (1965) (emphasis in original).
3. See, e.g., Stone v. Smith, Kline & French Laboratories, 731 F.2d 1575 (1 1th Cir. 1984)
(manufacturer's warning made to the physician instead of the consumer is adequate as a mat-
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warn only the prescribing physician has represented an exception to the
widely recognized rule of law that a manufacturer's product warnings must
reach the ultimate consumer in order for the producer to avoid liability for
harm caused by the product.4
As a result, prescription drug manufacturers have directed their warnings
toward physicians.5 In addition to these warnings, all other information
ter of law); Timm v. Upjohn Co., 624 F.2d 536, 538 (5th Cir.), cert. denied, 449 U.S. 1112
(1980) (the manufacturer has no duty to warn consumer of dangers of antibiotic drug "Cle-
ocin" where physician has been adequately warned); Reyes v. Wyeth Laboratories, 498 F.2d
1264, 1276 (5th Cir.), cert. denied, 419 U.S. 1096 (1974) (physician acts as learned intermedi-
ary and discharges manufacturer's duty to warn ultimate consumer of inherent dangers); Ster-
ling Drug, Inc. v. Cornish, 370 F.2d 82, 85 (8th Cir. 1966) (drug manufacturer has duty to
warn physician about dangers of arthritis drug "Aralen"); McElhaney v. Eli Lilly & Co., 575
F. Supp. 228 (D.S.D. 1983) (manufacturer has no duty to warn consumer of DES dangers
because physician acts as learned intermediary).
4. E.g., Reyes, 498 F.2d at 1276 (pharmaceutical manufacturers must warn ultimate pur-
chasers of nonprescription drugs); McPherson v. Buick Motor Co., 217 N.Y. 382, 111 N.E.
1050 (1916) (abolishing privity requirement in products liability cases); see also RESTATE-
MENT (SECOND) OF TORTS § 388 (1965), which states:
Chattel Known to be Dangerous for Intended Use
One who supplies directly or through a third person a chattel for another to use is
subject to liability to those whom the supplier should expect to use the chattel with
the consent of the other or to be endangered by its probable use, for physical harm
caused by the use of the chattel in the manner for which and by a person for whose
use it is supplied, if the supplier
(a) knows or has reason to know that the chattel is or is likely to be danger-
ous for the use for which it is supplied, and
(b) has no reason to believe that those for whose use the chattel is supplied
will realize its dangerous condition, and
(c) fails to exercise reasonable care to inform them of its dangerous condition
or of the facts which make it likely to be dangerous.
5. There are five basic methods that manufacturers use to communicate drug informa-
tion to physicians: the package insert; the Physician's Desk Reference [hereinafter cited as
PDR]; product cards (reproductions of the package insert); "Dear Doctor" letters (personal
letters sent directly to physicians); and pharmaceutical "detailmen" (salesmen who market
prescription drugs through personal visits to physicians).
The package insert is a written brochure included in the packaging of all prescription drugs.
The insert describes the characteristics of the drug compound and provides information on
warnings, adverse effects, dosages, contraindications and directions for use. See James, Warn-
ings and the Pharmaceutical Companies: Legal Status of the Package Insert, 16 HOUSTON L.
REV. 140 (1978). The PDR is an annually published compilation of the current package in-
serts for prescription drugs manufactured for use in the United States. Edited by the various
manufacturers and organized by brand name, generic name, and manufacturer, the PDR is
used by many physicians, nurses, and physician's assistants as a practical reference for basic
drug information. Product cards contain information identical to that in the PDR and are
distributed through detailmen and at medical conferences. "Dear Doctor" letters refer to cor-
respondences sent by manufacturers to physicians warning them of drug side effects which
have been newly identified. These, however, are not considered an effective means of warning
because the volume of such letters and other printed material that physicians receive by mail
precludes proper attention and assimilation by the physician. See Sterling Drug, Inc. v. Yar-
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necessary for the safe and effective use of prescription drugs has also been
directed toward the medical community. This is based upon the belief that
physicians, because of their education and experience, can best receive, un-
derstand and disseminate such information.6 Thus, consumers must obtain
almost all of the information necessary for the safe use of prescription drugs
through their doctor, or another health care professional acting on behalf of
their physician. The exact content of the information they receive is left to
the health professional's discretion. Liability for inadequate disclosure is
based on the doctrine of informed consent.7
This single-source informational system, however, may not be the most
effective means of assuring the safe use of prescription drugs. The system is
inadequate in communicating information if there is no meaningful physi-
cian-patient relationship.' This situation can frequently occur in mass im-
munization clinics and hospital emergency rooms. It also arises in situations
where drugs are prescribed by telephone or are reused by a patient for subse-
quent illness. In these instances, the physician often is not in a position to
row, 408 F.2d 978 (8th Cir. 1969). The pharmaceutical detailman is a salesperson employed
by the drug manufacturer to make personal visits to physicians for the purpose of marketing
drugs. Because the use of the detailman is such an effective method of communicating with
the physician, courts have held manufacturers liable for failing to warn through the detailman.
Yarrow, 408 F.2d at 992. In addition, manufacturers have been held liable when a detailman
so vigorously promotes a drug to the physician that an otherwise adequate warning becomes
inadequate. Stevens v. Parke, Davis & Co., 9 Cal. 3d 51, 67, 507 P.2d 653, 662, 107 Cal. Rptr.
45, 54 (1973); Incollingo v. Ewing, 444 Pa. 263, 289, 282 A.2d 206, 220 (1971).
6. Rheingold, Products Liability-The Ethical Drug Manufacturer's Liability, 18
RUTGERS L. REV. 947, 987 (1964), cited with approval in, Tinnerholm v. Parke, Davis & Co.,
285 F. Supp. 432, 440 (S.D.N.Y. 1976); Dyer v. Best Pharmaceutical, 118 Ariz. 465, 469, 577
P.2d 1084, 1088 (1978). Rheingold's oft quoted article summarizes the rationale for the
learned intermediary rule:
(1) [T]he doctor is intended to be an intervening party in the full sense of the
word. Medical ethics as well as medical practice dictate independent judgment, un-
affected by the manufacturer's control, on the part of the doctor. (2) Were the pa-
tient to be given the complete and highly technical information on the adverse
possibility associated with the use of the drug, he would have no way to evaluate it,
and in his limited understanding he might actually object to the use of the drug,
thereby jeopardizing his life. (3) It would be virtually impossible for a manufacturer
to comply with the duty of direct warning, as there is no sure way to reach the
patient.
Rheingold, supra at 987.
7. The doctrine of informed consent requires that a physician tell the patient "what a
reasonably prudent medical specialist would tell a person of ordinary understanding of the
serious risks and the possibility of serious harm which may occur from a proposed course of
therapy, so that the patient's choice will be an intelligent one." ZeBarth v. Swedish Hosp.
Medical Center, 81 Wash. 2d 12, 29, 499 P.2d 1, 11 (1972). The physician is not required to
disclose particular facts or warnings which he or she decides are not necessary to properly
inform the patient. McKee v. Moore, 648 P.2d 21, 24-25 (Okla. Sup. Ct. 1982).
8. See infra note 11.
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teach consumers all they need to know about the safe use of a drug. Even
where the traditional physician-patient relationship exists, a consumer may
not remember the warnings given verbally by the physician. The patient
may be hurried, anxious, intimidated or in pain. Thus, the single-source
informational system may result in poor application of the information made
available, thereby increasing the possibility of drug injury.9
The need for a multi-source informational system has been advocated in
Congress,' ° by the judiciary," and by the FDA.'2 In the past two decades,
there have been numerous strategies developed in an attempt to improve the
problems inherent in the single-source system. 13 All of these, however, have
9. See 44 Fed. Reg. 40,019-21 (1979) where the FDA summarized its review of the litera-
ture on the communication of drug information to patients. It has been postulated that five
areas must be examined in the communication process in order to determine whether patient
learning and retention has occurred. McGuire, Some Internal Psychological Factors Influenc-
ing Consumer Choice, 2 J. CONSUMER RESEARCH 302 (1976). To be properly educated, the
patient must be exposed to, pay attention to, understand, accept, and remember the informa-
tion communicated. 44 Fed. Reg. 40,019-20 (1979). Based on an analysis of the circumstances
of many doctor-patient communications about prescription drugs in light of these five factors,
the FDA determined that "oral communication of information about prescription drug prod-
ucts by health professionals to patients cannot be relied upon to provide patients with the
information they need to use prescription drug products properly." Id. at 40,020. See also
Cohen, What Drug Information Should the Consumer Have?-A Consumer Perspective, 11
DRUG INFO. J. 34, 35 (1977) (discussing how circumstances of doctor-patient communication
can lead to drug injury).
10. H.R. 11,611, 95th Cong., 2d Sess., 124 CONG. REC. 7369 (1978). Representative Paul
Rogers introduced H.R. 11,611 which included a prescription drug consumer labeling require-
ment. See infra note 113 for the labeling requirement text of the bill.
11. The judiciary has advocated a multi-source system where the absence of a physician
intermediary has led to drug injuries. See Givens v. Lederle, 556 F.2d 1341, 1345 (1977) and
Reyes, 498 F.2d at 1276 (both requiring the manufacturer to reach consumers with warnings
where polio vaccine was given at small country health clinics); Davis v. Wyeth Laboratories,
399 F.2d 121, 131 (9th Cir. 1968) (suggesting advertisements, posters, oral warnings, or patient
releases as alternative sources of information at a mass immunization clinic). Moreover,
courts have expressed a willingness to impose liability based on a reasonableness standard in
cases where no physician acts as an intermediary. See Dunn v. Lederle Laboratories, 121
Mich. App. 73, 79 n. 11, 328 N.W.2d 576, 579 n. 11 (1982) (warning must be designed to reach
the ultimate consumer where no doctor discretion is called upon); Smith v. E.R. Squibb &
Sons, 273 N.W.2d 476 (Mich. Sup. Ct. 1979) (warnings given to consumer where no doctor
intermediary must be examined as to their reasonableness under the circumstances).
12. See, e.g., 21 C.F.R. § 310.501(a)(1) (1984). The FDA's initiative for a multi-source
system was the Patient Package Insert (PPI) program. The PPI program was a major effort
spanning two decades aimed at providing consistent and easy-to-understand prescription drug
information to consumers. See infra notes 97, 102 and accompanying text.
13. Various methods can be used to communicate prescription drug information to the
consumer. See generally Morris, Printed Patient Oriented Prescription Drug Materials, 12
DRUG INTELLIGENCE & CLINICAL PHARMACY 161 (1978). These include stickers that are
affixed directly to the drug container, checklists containing numerous warnings and directions
that may be checked off by the pharmacist as appropriate. Id. at 163-64. Other methods
include drug information sheets that can be distributed by physicians or nurses in hospitals
[Vol. 34:117
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failed to provide consumers with a consistent, reliable source of prescription
drug information. There is a pressing need for such information. Prescrip-
tion drugs have become central to American lives,1 4 and are an absolute
necessity for some people.15 At the same time, the number of family-ori-
ented general practitioners has declined over the past 20 years.1 6 The tradi-
tional health care delivery system is being replaced by health maintenance
organizations (HMO), 7 clinics, and group practices. This change is leading
and clinics, and drug information written for the purpose of obtaining informed consent. Id. at
164, 167-68.
Stickers are instructional labels placed on the prescription drug containers by pharmacists
before the drug is dispensed. Typically, they warn patients to take medication with meals, to
avoid alcohol, to drink plenty of iluids, or to take medication on an empty stomach. Id. at 163.
Checklists are also dispensed by the pharmacist and contain instructions similar to those pro-
vided by stickers, although they vary in length and specificity. Id. Checklists often provide
more information than stickers, because the pharmacist can write special instructions on the
sheet. Id. Many hospitals prepare drug information sheets that contain information about
prescription drugs. Id. at 164. These sheets are given to the patients by the nurse upon dis-
charge from the hospital or when the patient is seen in a clinic. Although these sheets may
also be lost by the patient, they do provide specific and detailed drug information. Id.
Written drug information may also be combined with a consent form. The Center for Dis-
ease Control in Atlanta, Georgia disseminated one-page information sheets on the Swine Flu
Vaccine, containing a description of the vaccine and its side effects. Id. at 167. Individuals
were to sign the bottom of the sheet, indicating consent to be vaccinated. Id.
14. According to Pharmaceutical Data Services, 1.5 billion prescriptions were written in
the United States in 1983. 128 DRUG Topic MAG. 28 (March 1984).
15. For example, 11 million Americans currently suffer from diabetes. Further, some
500,000 children and young adults with the disease are insulin-dependent, requiring daily insu-
lin in order to live. AMERICAN DIABETES ASSOCIATION, DIABETES MELLITUS (1984).
16. In 1963, 73,489 physicians were identified as general practitioners. By 1982 this
number had declined to 62,339, despite a general growth in population during those years. See
AMERICAN MEDICAL ASSOCIATION, PHYSICIAN CHARACTERISTICS AND DISTRIBUTION IN
THE UNITED STATES (1963-1982). See also U.S. SENATE COMM. ON LABOR AND PUBLIC
WELFARE, SUBCOMM. ON HEALTH: HEALTH CARE CRISIS IN AMERICA (1971). A Consum-
ers Union consultant has commented on the problem of the disappearance of the traditional
doctor-patient relationship and the resulting problems:
The decline of the family doctor, the increase in specialization, greater patient mo-
bility, and time pressures on physicians all combine to make it less likely than ever
that the physician will be fully aware of the patient's history and physical idiosyncra-
sies that might affect successful drug use. A woman might neglect to mention to her
dentist or ophthalmologist that she may be pregnant, yet it may be very relevant to
their choice of drugs. Are these specialists likely to inquire? If the patient were more
knowledgeable, she would be far more likely to volunteer the critical information.
Cohen, supra note 9, at 35.
17. See 42 U.S.C. § 300e (1982). Section 300e defines a Health Maintenance Organization
and sets forth the manner in which it must supply health services to its members. Section
300e(b) states in pertinent part:
A health maintenance organization shall provide, without limitations as to time or
cost other than those prescribed by or under this subchapter, basic and supplemental
health services to its members in the following manner: (1) Each member is to be
provided basic health services for a basic health services payment . . . (3) . . . the
1984]
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to a decrease in the continuity of medical care received by consumers. It is
evident that if prescription drugs are to be used safely and effectively, the
consumer must be able to assist the prescribing physician in weighing the
risks and benefits of drug therapy, and in monitoring that course of therapy.
Without the increase in consumer knowledge that would accompany the es-
tablishment of a multi-source informational system, consumers can blindly
expose themselves to unnecessary dangers.
This Comment will describe the history and current status of consumer-
directed prescription drug information. It will analyze the ability of con-
sumer-directed information to address the failings of a single-source system
of prescription drug information. Finally, this Comment will explore some
alternative systems designed to communicate medication information to
consumers.
I. THE RIGHT TO PRESCRIPTION DRUG INFORMATION-DOES DOCTOR
ALWAYS KNOW BEST?
A. The Learned Intermediary Rule
It is well-settled that a drug manufacturer discharges its duty to warn the
ultimate user of prescription drugs by supplying physicians with information
about the drug's dangerous propensities. 18 This legal concept is known as
services of a physician which are provided as basic health services shall be provided
through-(i) members of the staff of the health maintenance organization, (ii) a med-
ical group (or groups), (iii) an individual practice association ....
18. Reyes, 498 F.2d at 1276. Judge Wisdom of the United States Court of Appeals for the
Fifth Circuit summarized this area of law in Reyes:
[W]here prescription drugs are concerned, the manufacturer's duty to warn is limited
to an obligation to advise the prescribing physician of any potential dangers that may
result from the drug's use. . . . Prescription drugs are likely to be complex
medicines, esoteric in formula and varied in effect. As a medical expert, the prescrib-
ing physician can take into account the propensities of the drug, as well as the sus-
ceptibilities of his patient. His is the task of weighing the benefits of any medication
against its potential dangers. The choice he makes is an informed one, an individual-
ized medical judgment bottomed on a knowledge of both patient and palliative.
Id. (footnote omitted, emphasis in original). See also, Mauldin v. Upjohn Co., 697 F.2d 644
(5th Cir.), cert. denied, 104 S. Ct. 155 (1983) (manufacturer not obliged to warn consumer of
antibiotic drug "Cleocin" if physician adequately warned); Brochu v. Ortho Pharmaceutical
Co., 642 F.2d 652 (1st Cir. 1981) (manufacturer must warn the physician, not the patient, of
dangers involved in use of prescription drugs); Goodson v. Searle Laboratories, 471 F. Supp.
546 (D. Conn. 1978) (manufacturer had duty to warn only prescribing physician); McKee v.
Moore, 648 P.2d 21 (Okla. Sup. Ct. 1982) (manufacturer had duty to warn only the physician
of IUD side effects); Dyer v. Best Pharmaceutical, 118 Ariz. 465, 468, 577 P.2d 1084, 1087
(1978) (manufacturer's duty to public discharged with proper warning to physician); Terhune
v. A. H. Robins Co., 90 Wash. 2d 9, 16-17, 577 P.2d 975, 979 (1978) (IUD manufacturer not
required to warn public).
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the learned intermediary rule because the physician acts as an intermediary
between the manufacturer and the consumer. The phrase "learned interme-
diary" was first given legal significance in 1966, in Sterling Drug, Inc. v.
Cornish, 9 where it was used to describe the physician's unique role in the
dissemination of prescription drug warnings. Cornish involved an action
against a drug manufacturer for failure to warn a prescribing physician
about a rare, but serious side effect caused by the use of its anti-arthritic drug
"Aralen." z The plaintiff in Cornish suffered irreversible degeneration of the
retina, resulting in extensive vision impairment.2 At issue was whether the
manufacturer had a duty to warn the plaintiff's physician of the existence of
this rare side effect. The court held that it did,22 and although discussion of
the learned intermediary rule was not extensive, the term has since become
synonymous with the rule that by warning the physician of possible drug
side effects a drug manufacturer need not warn the ultimate consumer. The
court reasoned that the intermediary role of the physician provided the best
means of preventing drug-induced injury.23 Provided with the knowledge of
possible side-effects from the manufacturer's warnings, the physician would
be able to monitor the patient for adverse symptoms, safeguarding the pa-
tient from injury. 24 The court did not address the question of whether drug
safety might be further enhanced by additional warnings to the consumer.
Clearly, however, a warning to the physician was viewed as being of primary
importance in discharging the manufacturer's duty to warn.25
Prior to the decision in Cornish, the learned intermediary rule had not
been clearly defined. In an earlier case where the issue was considered, how-
ever, the court permitted manufacturers to warn the physician in lieu of the
consumer. In Love v. Wolf,26 the Court of Appeals for the Third District of
California held that the manufacturer of the antibiotic, "chloromycetin,"
19. 370 F.2d 82, 85 (8th Cir. 1966). Judge McManus of the United States Court of Ap-
peals for the Eighth Circuit introduced the term in Cornish:
[I]n this case we are dealing with a prescription drug rather than a normal con-
sumer item. . . . [Tihe purchaser's doctor is a learned intermediary between the
purchaser and the manufacturer. If the doctor is properly warned of the possibility
of a side effect in some patients, and is advised of the symptoms normally accompa-
nying the side effect, there is an excellent chance that injury to the patient can be
avoided.
Id.
20. Id. at 83.
21. Id. at 84.
22. Id. at 85.
23. Id. See supra note 19, for the language of the court.
24. 370 F.2d at 85.
25. Id.
26. 226 Cal. App. 2d 378, 38 Cal. Rptr. 183 (1964).
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had no duty to warn the patient for whom the drug was prescribed about the
possibility of developing severe, life-threatening anemia.2 7 The plaintiffs
physician had prescribed "chloromycetin" for various minor conditions such
as a sore gum and bronchitis." Each prescription was refilled several
times. 29 A few months later, the plaintiff developed aplastic anemia, a de-
generative disease of the bone marrow, which required extensive treatment
under the care of a hematologist.3" The manufacturer had warned the medi-
cal community of the relationship between aplastic anemia and prolonged
use of "chloromycetin" in all its advertising literature. 3 ' The court held that
the manufacturer's warnings were sufficient to shift the duty of informing
the plaintiff from the manufacturer to the physician.32 As a matter of law,
the court held that by adequately warning the plaintiff's physician, reason-
able care had been exercised to warn the small percentage of users who
might have been harmed by the drug.3 3 The court implied that it was not
willing to require a manufacturer to warn all potential users when efforts
had already been made to warn the medical profession.34
Two years later, the learned intermediary rule was developed further and
an exception was introduced. In Davis v. Wyeth,3 5 the manufacturer of the
Sabine polio vaccine was sued by a consumer who contracted polio after the
vaccine was administered at a mass immunization clinic. The plaintiff re-
ceived no warning about the risk of contracting polio from the vaccine. 36
However, each 100-dose batch of the vaccine contained a written warning of
the risk of contracting polio.3 7 The United States Court of Appeals for the
27. Id. at 395, 38 Cal. Rptr. at 193. The court stated that:
[i]n the case of a drug it has been held there is a duty to exercise reasonable care to
warn of potential dangers from use even though the percentage of users who will be
injured is not large. But if adequate warning of potential dangers of a drug has been
given to doctors, there is no duty by the drug manufacturer to insure that the warn-
ing reaches the doctor's patient for whom the drug is prescribed.
Id. (citations omitted).
28. Id. at 384, 39 Cal. Rptr. at 186.
29. Id.
30. Id.
31. Id. at 395, 38 Cal. Rptr. at 193.
32. Id. The court noted that the manufacturer warned that adequate blood studies should
be made during prolonged use of the drug and that the drug should not be used for minor
infections. Id. These warnings were included in letters written to every physician in the
United States. Id. The court estimated that the company had publicized warnings to the
medical profession between 85 and 90 million times during the period from the introduction of
the drug to the occurrence at trial. Id.
33. Id.
34. Id.
35. 399 F.2d 121 (9th Cir. 1968).




Ninth Circuit imposed liability upon the manufacturer for failing to warn
the consumer because in the case of a mass immunization clinic, no physi-
cian is present to weigh the risks and benefits of drug therapy for each indi-
vidual patient."8 Although the court created an exception to the learned
intermediary rule in Davis, it also set forth explanatory language that be-
came the basis of the rule for other courts. Regarding the learned intermedi-
ary rule, the court stated that ordinarily a warning to the physician was "the
only effective means by which a warning could help the patient."39 The rule
is based upon the fact that the choice of treatment with a prescription drug is
a medical one, and must be made with the knowledge of the medical consid-
erations involved.' The language in Davis regarding the learned intermedi-
ary rule has been quoted by many courts,4" and the rule is widely followed
today.42
The learned intermediary issue has never been addressed by the Supreme
Court, but various federal courts have reaffirmed its validity.43 Most re-
cently, the United States Court of Appeals for the Eleventh Circuit affirmed
an Alabama Supreme Court decision denying relief for a drug-induced hepa-
titis because the physician had been adequately warned. In Stone v. Smith,
Kline & French Laboratories," the court refused to depart from the tradi-
tional concept of the learned intermediary in holding that the manufacturer
of "Thorazine", an anti-psychotic drug, could not be held strictly liable for
causing liver damage.45 The plaintiff had been treated with "Thorazine"
while hospitalized for a psychotic illness and was instructed to continue tak-
ing the drug after discharge from the hospital.46 The plaintiff developed
38. Id. at 131. See infra note 86 for the language of the court.
39. 399 F.2d at 130 (footnoted omitted).
40. Id. The court stated: "Ordinarily in the case of prescription drugs [sic] warning to
the prescribing physician is sufficient. . . . [T]he choice involved is essentially a medical one
involving an assessment of medical risks in the light of the physician's knowledge of his pa-
tient's needs and susceptibilities." Id.
41. E.g., Schenebeck v. Sterling, Inc., 423 F.2d 919, 922 (8th Cir. 1970); Goodson v.
Searle Laboratories, 471 F. Supp. 546, 548 (D. Conn. 1978); Ortho Pharmaceutical Corp. v.
Chapman, 388 N.E.2d 541, 549 (Ind. Ct. App. 1979); Terhune v. A.H. Robins Co., 90 Wash.
2d 9, 14, 577 P.2d. 975, 978 (1978).
42. See infra notes 43, 63 and accompanying text.
43. See, e.g., Stone v. Smith, Kline & French Laboratories, 731 F.2d at 1579; DeLuryea v.
Winthrop Laboratories, 697 F.2d 222, 225 (8th Cir. 1983) (quoting Cornish, 370 F.2d at 85);
Mauldin, 697 F.2d at 647; Brochu, 642 F.2d at 656; Lindsay v. Ortho Pharmaceutical Corp.,
637 F.2d 87, 90-91 (2d Cir. 1980).
44. 731 F.2d 1575 (11th Cir. 1984).
45. Id. at 1579-80. The court quoted the learned intermediary language of Reyes and
based its decision on the Reyes court's "sound reasoning." Id. at 1580. See supra note 18 for
the language of the Reyes court.
46. Id. at 1577.
1984]
Catholic University Law Review
symptoms of liver disease shortly thereafter and was diagnosed with choles-
tatic jaundice, a liver condition known to be a risk of "Thorazine" use.47
The plaintiff asserted that because the risk from cholestatic jaundice was
small, the physician was unable to predict the occurrence of an adverse reac-
tion.4 ' Thus, the plaintiff argued, the physician was unable to make an in-
formed choice in prescribing "Thorazine. ' 49 The court rejected plaintiff's
argument, reasoning that the physician's role was to balance the known risks
and benefits of drug therapy.5" The court inferred that the possibility of a
rare adverse reaction would be factored into the physician's balancing test
for every patient, even though the physician would not know which patients
may suffer injury.5"
The United States Court of Appeals for the Fifth Circuit also upheld the
learned intermediary rule in Mauldin v. Upjohn Co..52 In Mauldin the plain-
tiff developed ulcerative colitis after using two antibiotics produced by the
defendant, "Cleocin" and "Lincocin." 53 Ulcerative colitis is a condition of
the bowel frequently requiring extensive surgical treatment.54 The issue was
whether the plaintiff's physician had been adequately warned of the risk of
ulcerative colitis that the two drugs posed.55 The plaintiff's physician testi-
fied that even if the manufacturer had communicated the risk of this adverse
effect, the physician might not have alerted the patient to the possibility of
its occurrence.56 The physician stated that patients were not always told
about all of the side effects of drug therapy.57 In this case, the plaintiff suf-
fered from prolonged diarrhea, a symptom of ulcerative colitis, after being
discharged from the primary physician's care. 8 The plaintiff was examined
47. Id. at 1577, 1579.
48. Id. at 1579.
49. Id.
50. Id. at 1579-80 (citing Reyes, 498 F.2d at 1276).
51. Id.
52. 697 F.2d 644 (5th Cir. 1983).
53. Id. at 645-46.
54. See generally T. HARRISON, PRINCIPLES OF INTERNAL MEDICINE (9th ed. 1983).
55. 697 F.2d at 646. The court noted that the warning on the package insert contained
the following information:
WARNINGS
The following reactions have been reported with the use of clindamycin [Cleocin]
CASES OF SEVERE AND PERSISTENT DIARRHEA HAVE BEEN RE-
PORTED AND HAVE AT TIMES NECESSITATED DISCONTINUANCE OF
THE DRUG. THIS DIARRHEA HAS BEEN OCCASIONALLY ASSOCIATED
WITH BLOOD AND MUCUS IN THE STOOLS AND HAS AT TIMES RE-
SULTED IN ACUTE COLITIS.
Id. at 646 n.2.
56. Id. at 646-47 n.4.
57. Id.
58. Id. at 645.
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by several different doctors who prescribed treatment, apparently unaware
of the plaintiffs medical history. 9 The court held that the adequacy of the
warnings to the primary physician was a question of fact for the jury,6° but
that there was no obligation to warn the plaintiff of the potential adverse
effects.6 The manufacturer could have discharged its duty by adequately
warning the physician.
62
State courts have also generally followed the learned intermediary rule.
63
In Terhune v. A.H. Robins Co.,' the plaintiff suffered a perforated uterus
and abdominal infection resulting from the migration of an intrauterine de-
vice (IUD), the Dalkon Shield, manufactured by the defendant. The Wash-
ington Supreme Court expanded the learned intermediary rule to apply it to
devices, such as the Dalkon Shield, which can only be obtained through a
prescription. 6' The plaintiff was not told by her physician of the possibility
of perforation when the advantages and disadvantages of methods of contra-
ception were discussed.66 Nevertheless, the court held that a warning to the
physician about the possibility of perforation was sufficient, because it was
the physician's duty to exercise independent judgment in deciding what to
inform the patient.67
Bacardi v. Holzman68 is another example of a state's acceptance of the
learned intermediary rule. In Bacardi, the plaintiff contended that defendant
drug manufacturer, Lederle Laboratories, had a duty to warn about the pos-
sibility of glaucoma from ingestion of "Diamox," a drug used for the treat-
ment of kidney stones.69 A New Jersey superior court, however, relying on
59. Id.
60. Id. at 647.
61. Id. The court stated that "[t]he manufacturer of a prescription drug is not obliged to
warn each consumer of the dangers inherent in the use of its product if the prescribing physi-
cian receives adequate warnings of the potential adverse effects. Id.
62. Id.
63. See, e.g., Bacardi v. Holzman, 182 N.J. Super. 422, 442 A.2d 617 (1981); Ortho Phar-
maceutical Corp. v. Chapman, 388 N.E.2d 541 (Ind. Ct. App. 1979); Smith v. E.R. Squibb &
Sons, 273 N.W.2d 476 (Mich. Sup. Ct. 1979); Terhune, 90 Wash. 2d 9, 577 P.2d 975 (1978).
64. 90 Wash. 2d 9, 577 P.2d 975 (1978).
65. Id. at 14-15, 577 P.2d at 978.
66. Id. at 10, 577 P.2d at 976.
67. Id. at 14-16, 577 P.2d at 978-79. The court stated that
[i]t is [the physician's] duty to [keep informed] of the qualities and characteristics of
those products which he prescribes for or administers to or uses on his patients, and
to exercise an independent judgment, taking into account his knowledge of the pa-
tient as well as the product. The patient is expected to and, it can be presumed, does
place primary reliance upon that judgment. The physician decides what facts should
be told to the patient.
Id. (footnoted omitted).
68. 182 N.J. Super. 422, 442 A.2d 617 (1981).
69. Id. at 424, 442 A.2d at 618.
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the learned intermediary principles in Davis,7" held that a drug manufac-
turer had no such duty. The plaintiff asserted that the learned intermediary
rule should not apply because there was no individual balancing of the risks
and benefits of treatment. The plaintiff had been treated with the drug for
many years, and had renewed the prescription as often as thirteen times in
seventeen months.7 ' Because the plaintiff-patient had seen so many doctors,
he was unable to name them all.72 The plaintiff argued that under these
circumstances, the duty to warn should have been extended to the user of the
drug.73 The court, however, held fast to the learned intermediary rule, stat-
ing that the physician's diagnosis and treatment of the patient removed the
case from the reasoning of Davis.74 The court reasoned that Davis and Reyes
applied only where the prescription drug was not dispensed by a physician,
as in the mass immunization cases. The court held that the exception only
existed where "the unique method of administration of the prescription drug
extended the duty to warn beyond the physician.,
75
The learned intermediary concept was again addressed in McKee v.
Moore,76 an Oklahoma case involving injuries sustained when an IUD perfo-
rated the plaintiff's uterus and migrated into her abdominal cavity.
77
Although neither plaintiff nor her husband was informed of the possibility of
perforation when they chose the IUD as a form of contraception, the
Oklahoma Supreme Court denied plaintiff's claim because the manufacturer
had included the warning of possible perforation in the package insert. 8
The learned intermediary, the court concluded, not the patient, had the pri-
mary responsibility of deciding whether the benefits of the IUD outweighed
the risk.79
70. Id. at 425, 442 A.2d at 619. The court quoted and relied upon the language of Davis,
399 F.2d 121 (9th Cir. 1968), infra note 86. It also acknowledged "the general rule that in the
case of prescription drugs[,] warnings of potential adverse effects to the prescribing physician
[are] sufficient." Id. at 425, 442 A.2d at 619.
71. Id. at 427, 442 A.2d at 620.
72. Id. at 425, 422 A.2d at 619.
73. Id.
74. Id. at 426, 442 A.2d at 619. See infra note 86 and accompanying text.
75. 182 N.J. Super. at 427, 442 A.2d at 620.
76. 648 P.2d 21 (Okla. Sup. Ct. 1982).
77. Id. at 22-23.
78. Id. at 23, 25.
79. Id. at 24. The court stated:
[T]he duty of a manufacturer is satisfied if an adequate warning is given to the pre-
scribing physician. In the absence of FDA regulations to the contrary, the manufac-
turer had no obligation to warn a consumer. . . . The manufacturer's duty is to
warn the physician, who acts as a learned intermediary between the manufacturer
and the consumer, because he is in the best position to evaluate the patient's needs,
assess the benefits and risks of a particular therapy, and to supervise its use.
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Thus, courts have traditionally viewed a warning to the physician as the
most effective means of relieving the manufacturer of its duty and assuring
that the consumer will be adequately warned as well.8" The manufacturer's
duty to warn may be discharged by a physician in various ways. The physi-
cian may either communicate all or part of the warnings provided by the
manufacturer, or may personally weigh the risks and benefits of the drug,
never imparting knowledge of the dangers to the consumer. 81 The physi-
cian's duty is to make an informed decision regarding the administration of
each drug based on knowledge, experience and judgment. 82 The consumer is
expected to rely on this decision, whether or not the physician has chosen to
disclose all the facts.83
B. Addressing the Problems of the Learned Intermediary Rule-Judicial
Exceptions and Agency Rulemaking
1. Judicial Exceptions to the Rule
Despite judicial acceptance of the learned intermediary rule, the rule has
proven inadequate in some cases. 84 For example, while Davis spells out the
learned intermediary rule, it also introduces the exception to it. In Davis, the
manufacturer of the polio vaccine had knowledge that the drug would be
dispensed to all individuals who came to a mass immunization clinic.8 5
Although individual vials sold to the medical clinic contained package in-
serts with adequate warnings, the court held the manufacturer's duty was
not discharged by warning only the medical personnel.8 6 The court stated
Id.
80. Davis, 399 F.2d at 130; Cornish, 370 F.2d at 85; Love, 226 Cal. App. 2d at 394, 38 Cal.
Rptr. at 193.
81. McKee, 648 P.2d at 24-25.
82. Id.
83. Id. The court quoted the Terhune language supra note 67 and also stated that an
exception to this general rule exists where there is an FDA regulation mandating a consumer
warning. Id.
84. See Givens v. Lederle, 556 F.2d 1341 (5th Cir. 1977); Reyes v. Wyeth Laboratories,
498 F.2d 1264 (5th Cir.), cert. denied, 419 U.S. 1096 (1974); Davis v. Wyeth Laboratories, 399
F.2d 121 (9th Cir. 1968); Dunn v. Lederle Laboratories, 121 Mich. App. 73, 328 N.W.2d 576
(1982).
85. 399 F.2d at 131.
86. Id. The court stated that:
although the drug was denominated a prescription drug it was not dispensed as such.
It was dispensed to all comers at mass clinics without an individualized balancing by
a physician of the risks involved. In such cases (as in the case of over-the-counter
sales of nonprescription drugs) warning by the manufacturer to its immediate pur-
chaser will not suffice. The decision (that on balance and in the public interest the
personal risk to the individual was worth taking) may well have been that of the
medical society and not of [the patient]. But just as the responsibility for choice is
19841
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that "the responsibility for choice is not one that a manufacturer can...
allow his immediate purchaser to assume. [I]t is the responsibility of the
manufacturer to see that the warnings reach the consumer., 8 7 The court
suggested the manufacturer advertise prior to or during the operation of the
immunization clinics, and issue releases to be read and signed by consumers
at the clinic as possible means of discharging the manufacturer's duty. 8
In 1974, the United States Court of Appeals for the Fifth Circuit applied
the Davis exception to the learned intermediary rule in another immuniza-
tion case. Reyes v. Wyeth 89 involved an eight-month-old baby who con-
tracted polio after immunization with live polio virus produced by Wyeth
Laboratories.9" Although the decision contains language reaffirming the
learned intermediary rule,9 ' the court found that in an immunization case,
where there is no physician present to weigh the individual risks and benefits
of therapy, the "very justification for the prescription drug exception evapo-
rates."92 Liability was imposed on Wyeth for failing to warn the consumer
since the vaccine was given in a small health clinic without the benefit of a
physician intermediary. 93
Recently, the Michigan Court of Appeals recognized an exception to the
learned intermediary rule in a footnote in another immunization case. In
Dunn v. Lederle,94 the plaintiff contracted polio from her daughter, who was
not one that the manufacturer can assume for all comers, neither is it one that he can
allow his immediate purchaser to assume. In such cases, then, it is the responsibility
of the manufacturer to see that warnings reach the consumer, either by giving warn-




89. 498 F.2d 1264 (5th Cir. 1974).
90. Id. at 1269.
91. Id. at 1276. The court stated:
we cannot quarrel with the general proposition that where prescription drugs are con-
cerned, the manufacturer's duty to warn is limited to an obligation to advise the
prescribing physician of any potential dangers that may result from the drug's use.
This special standard for prescription drugs is an understandable exception to the
Restatement's general rule that one who markets goods must warn forseeable ulti-
mate users of dangers inherent in his products.
Id. (footnote omitted, emphasis in original).
92. Id. Relying on Davis, the court added:
[A]s in the case of patent drugs sold over the counter without prescription, the manu-
facturer of a prescription drug who knows or has reason to know that it will not be
dispensed as such a drug must provide the consumer with adequate information so
that he can balance the risks and benefits of a given medication himself. . . . [T]he
manufacturer is required to warn the ultimate consumer, or to see that he is warned.
Id.
93. Id. at 1277.
94. 121 Mich. App. 73, 328 N.W.2d 576 (1982).
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vaccinated with a live polio virus.95 The court approved the learned inter-
mediary rule and applied it to the case, but stated in dicta that where no
physician is available to exercise a medical judgment, the manufacturer must
reach the consumer with the warning.96 The court did not suggest how this
standard was to be applied, leaving prescription drug manufacturers unsure
of how this would affect future litigation. As the cases illustrate, the excep-
tion to the learned intermediary rule is narrow and has only been acknowl-
edged by the judiciary where no physician provides an individualized
balancing of the risks and benefits of a prescription drug.
2. The Patient Package Insert Model: The Administrative Answer to
the Learned Intermediary Problem
The Food and Drug Administration's dissatisfaction with judicial formu-
lation of the learned intermediary rule inspired an initiative to change the
single-source informational system. Beginning in 1970, the FDA promul-
gated regulations requiring manufacturers to provide consumer-directed in-
formation with oral contraceptives, estrogen products, intrauterine devices,
and progestational drugs.97 The FDA required the manufacturer to include
patient package inserts (PPIs) with the drug packaging in recognition that
95. Id. at 76, 328 N.W.2d at 578.
96. Id. at 79 n.11, 328 N.W.2d at 579 n.ll. The footnote states that "[i]f a doctor's
discretion is not called upon, e.g., through mass immunization or nonprescription drugs, warn-
ings must be calculated to reach the ultimate consumer."
97. See 21 C.F.R. § 310.516 (1978); 21 C.F.R. § 310.515 (1977); 21 C.F.R. § 310.501
(1970); 21 C.F.R. § 310.502 (1970). The first oral contraceptive labeling was proposed in
April 1970 by former FDA Commissioner Charles C. Edwards. 35 Fed. Reg. 5962 (1970).
The agency was aware that patient labeling represented a departure from the single-source
informational system, but stated that factual information about the possible side effects and
risks of oral contraceptives should be given to the users of these drugs. The agency considered
the following factors in requiring patient labeling as a means of promoting the safe use of oral
contraceptives: (1) that oral contraceptives are potent hormonal drugs; (2) that oral contra-
ceptives are used by large numbers of healthy women for long periods of time; (3) that the
majority of oral contraceptive use is elective in that other methods of contraception could be
substituted; and (4) that because the drugs are contraceptives, they tend to be transferred
between persons and used without adequate medical supervision. The text of the proposed
labeling was as follows:
Oral Contraceptives
(Birth Control Pills)
The oral contraceptives are powerful, effective drugs. Do not take these without
your doctor's continued supervision. As with all effective drugs, they may cause side
effects in some cases and should not be taken at all by some. Rare instances of abnor-
mal blood clotting are the most important known complication of the oral contracep-
tives. These points were discussed with you when you chose this method of
contraception. While you are taking this drug, you should have periodic examina-
tions at intervals set by your doctor. Notify your doctor if you notice any of the
following:
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these drugs were being used on an elective basis by large numbers of healthy
women, 98 that they were potentially dangerous, and, perhaps most impor-
tantly, that there was no assurance that the users of the products were being
adequately warned about their dangers.9 9
Based on several considerations, including studies of the effectiveness of
PPIs for these four products," ° the FDA determined that consumer-di-
rected information was necessary for the safe and effective use of all pre-
scription drugs, whether or not they were being used electively or for general
treatment of disease.' ° ' In 1979, the FDA proposed regulations requiring
PPIs for almost all prescription drugs.'0 2 At the heart of this proposal was
1. Severe headache
2. Blurred vision
3. Pain in the legs
4. Pain in the chest or unexplained cough
5. Irregular or missed periods
Id. Patient labeling for diethylstilbestrol (DES) regarding its use as a post-coital oral contra-
ceptive (the "morning-after" pill) was later added to § 310.501. 38 Fed. Reg. 26,809 (1973).
98. The Advisory Committee on Obstetrics and Gynecology estimated that as of 1969, 8.5
million women used oral contraceptives in the United States for contraceptive purposes. FDA,
SECOND REPORT ON THE ORAL CONTRACEPTIVES BY THE ADVISORY COMM. ON OBSTET-
RICS AND GYNECOLOGY 3 (1969).
99. 40 Fed. Reg. 5351 (1975); 21 C.F.R. § 310.501(a)(1) (1978).
100. 44 Fed. Reg. 40,017 (1979). The FDA reviewed the literature available on consumer
information for prescription drug products, sponsored several nationwide surveys and per-
formed independent research to evaluate its PPI program. For a bibliography of surveys and
studies, see 44 Fed. Reg. 40,035-38 (1979). Generally, it was found that patients desired more
complete information about prescription drug products. See, e.g., Fleckenstein, Oral Contra-
ceptive Patient Information: A Questionnaire Study of Attitudes, Knowledge, & Preferred Infor-
mation Sources, 235 J.A.M.A. 1331 (1976); Joubert, Patient Package Inserts' I. Notion,
Nature, and Needs, 18 CLINICAL PHARMACOLOGY & THERAPEUTICS 507 (1975); Joubert,
Patient Package Inserts, 11. Toward a Rational Patient Package Insert, 18 CLINICAL PHARMA-
COLOGY & THERAPEUTICS 663 (1975).
101. See 45 Fed. Reg. 60,764 (1980). Regarding the final regulations establishing PPI re-
quirements, 45 Fed. Reg. 60,754, the FDA stated:
FDA does not agree that information about serious adverse reactions and safety
hazards should only be required for so-called 'elective' drug products. The agency is
confident that most patients can participate in the evaluation of the risks and benefits
from drug products even when the use is not elective, and has revised the require-
ment to state specifically that patient package inserts must advise the patient of those
adverse reactions and safety hazards that may help the patient evaluate the benefits
and risks of the drug. There is no reason to believe that warning information about
nonelective products will be any more or less confusing, frightening, or incomprehen-
sible than similar statements about any elective drug. A patient who is informed
about the potential adverse effects of a drug product is better able to monitor his or
her reactions to the product and to take appropriate action if an adverse effect
occurs.
45 Fed. Reg. 60,764 (1980).
102. 44 Fed. Reg. 40,016 (1979). Based on its authority to assure the safe and effective use
of drug products through the monitoring of drug labeling, 21 U.S.C. §§ 355(d), (e), the FDA
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the FDA's conviction that the learned intermediary rule and the single-
proposed regulations requiring PPIs for nonelectively used prescription drugs. The agency's
goal was to promote the safe and effective use of prescription drug products by patients and to
ensure that patients have the opportunity to be informed of the benefits and risks involved in
the use of prescription drug products. See 44 Fed. Reg. 40,016 (1979). The agency noted that
the practice of providing prescription drug information solely to the physician did not en-
courage the safe use of prescription drugs. Id. at 40,017. Former Commissioner Donald Ken-
nedy gave insight into the FDA rationale behind the PPI program by stating "[The FDA]
bring[s] to this process no preconceived conclusions, other than the conviction that some way
must be found to demystify the relationship between the physician and the patient." Kennedy,
Remarks of the Commissioner, 32 FOOD DRUG COSM. L.J. 384, 387 (1977). Kennedy urged
physicians to "look at patient labeling not as an intrusion, but as an educational resource for a
particular drug. . . . [K]nowledge raises the quality of discourse between patient and physi-
cian, eliminates unfounded apprehension, increases compliance and draws the patient into ac-
tive participation." Id. at 386-87. The agency cited several studies showing that consumers
wanted and needed more information about prescription drugs. Eighty-eight percent to
ninety-seven percent of 1,720 oral contraceptive users responding in a nationwide survey stated
that they would like to receive patient labeling for other types of drugs including antibiotics,
cough and cold medications and tranquilizers. Mazis, Patient Attitudes About Two Forms of
Oral Contraceptive Information, 16 MEDICAL CARE 1045, 1051 (1978). Likewise, a national
study of 2,002 adults showed that two out of three individuals responding believed that patient
labeling was an important adjunct to oral consultations with physicians. THE ROPER ORGAN-
IZATION, ROPER REPORTS no. 78-3, (1978). The FDA also conducted extensive public discus-
sions on the issue of PPIs, including a national symposium sponsored jointly by the FDA, the
Drug Information Association (DIA) and the American Medical Association (AMA). Over
700 health professionals, interested organizations, and consumer representatives attended the
symposium held in 1976. The proposed regulations were also based on the evaluation of over
1,000 comments received from the November 7, 1975 notice of rulemaking, 40 Fed. Reg.
48,918 (1975), 750 of which were from consumers who favored patient labeling, 44 Fed. Reg.
40,019 (1979), and on a review of a consumer consortium petition in 1975 asking the FDA to
require patient labeling. Id. at 40,018. Members of the consortium included the Consumers
Union, Consumer Action for Improved Food and Drugs, the National Organization for Wo-
men, the Women's Equity Action League, and the Women's Legal Defense Fund. Id.
Examples of the type of labeling which would be acceptable under the proposed regulations
were provided by the FDA. 45 Fed. Reg. 60,788 (1980). The example for propoxyphene,




Propoxyphene is used to relieve pain but can be dangerous when mixed with other
drugs or alcohol. Limit your intake of alcohol when taking this drug. Also do not
take any tranquilizers, sleep aids, antidepressants, antihistamines, or any other drugs
that make you sleepy unless your doctor tells you to do so. Combining any of these
with propoxyphene may lead to an overdose.
Propoxyphene may make you sleepy. Use care driving a car or using machines until
you see how the drug affects you. Do not take more of the drug than your doctor
prescribed. Dependence has occurred when patients have taken propoxyphene for a
long period of time at a dose greater than recommended.
The rest of this leaflet gives you more information about propoxyphene. Please
read it and keep it for future use.
Cautions
Other drugs: Combinations of excessive doses of propoxyphene, alcohol, and tran-
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source informational system it had generated were inadequate to insure the
safe and effective use of prescription drugs.' °3 The FDA contended that
PPIs would facilitate the safe use of prescription drugs by reinforcing drug
information given by the physician."° It argued that in the traditional phy-
quilizers may be dangerous. Make sure your doctor knows you are taking tranquiliz-
ers, sleep aids, antidepressant drugs, antihistimines, or any other drugs that make
you sleepy. The use of these drugs with propoxyphene increases their sedative effects
and may lead to overdose symptoms, including death (see "Overdose" below).
Alcohol: Heavy use of alcohol with propoxyphene is hazardous and may lead to
overdosage symptoms (see "Overdose" below). THEREFORE, LIMIT YOUR IN-
TAKE OF ALCOHOL WHILE TAKING PROPOXYPHENE.
Regular Activities: Propoxyphene may cause drowsiness or impair your mental
and/or physical abilities, therefore, use caution when driving a vehicle or operating
dangerous machinery. DO NOT perform any hazardous task until you have seen
your response to this drug.
Who Should Not Take Propoxphyene
Do not take propoxyphene during pregnancy unless your doctor knows you are
pregnant and specifically recommends its use.
The effects of propoxphyene in children under 12 has not been studied. Therefore
use in this group is not recommended.
Make sure your doctor knows if you have ever had an allergic reaction to propox-
yphene, aspirin, or acetominophen.
Some forms of propoxyphene contain aspirin to help relieve the pain. Do not take
propoxyphene in this form if you have ulcers or if you are taking an anti-coagulant
("blood thinner"). The aspirin may irritate the ulcer and cause it to bleed . ...
Overdose
An overdose of propoxyphene alone or in combination with other drugs including
alcohol is likely to exaggerate the drug's normal effects. It may cause extreme drow-
siness, weakness, breathing difficulties, and confusion. A large overdose may lead to
unconsciousness and death.
When the propoxyphene product contains acetominophen, overdose symptoms are
nausea, vomiting, lack of appetite and abdominal pain. An overdose may lead to
liver damage, coma and death.
When the propoxyphene product contains aspirin, symptoms of taking too much
of the drug are headache, dizziness, ringing in the ears, difficulty hearing, dim vision,
confusion, drowsiness, sweating, thirst, rapid breathing, nausea, vomiting and occa-
sionally, diarrhea.
In any suspected overdose situation, GET EMERGENCY HELP IMMEDI-
ATELY. Keep this drug and all drugs out of the reach of children.
Possible Side Effects
When propoxyphene is taken as directed, side effects are infrequent. Among those
reported are drowsiness, dizziness, nausea, and vomiting. If these effects occur, it
may help to lie down and rest.
Less frequently reported side effects are constipation, abdominal pain, skin rashes,
lightheadedness, headache, weakness, minor visual disturbances, and feelings of ela-
tion or discomfort.
If any of these side effects occur and becomes bothersome, contact your doctor.
45 Fed. Reg. 60,796-98 (1980).
103. See Kennedy, supra note 102, at 386-87.
104. 44 Fed. Reg. 40,020 (1976).
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sician's office setting, the information is usually given on a one-time, verbal
basis. The recipient may be anxious or ill. In addition, drug information is
usually given at the conclusion of an office visit, after the patient has already
been exposed to possibly disturbing information regarding diagnosis and
plan of care. The FDA maintained that a written source of information that
the patient can read and refer to continuously would be an effective means of
reinforcing the information given by the physician and serve as a standing
reminder to the patient of the proper purposes and use of the prescribed
drug. 105
Comments received in response to the notice of proposed rulemaking on
the PPI program indicated strong public dissatisfaction with the single-
source informational system.° 6 While physicians were considered to be the
most important source of prescription drug information, consumers desired
supplemental information because they did not feel adequately knowledgea-
ble about the drugs they took.1 °7 On the other hand, various medical and
pharmaceutical groups argued that the public interest would not be served
by consumer-directed labeling.'0° Their opposition was based on the belief
105. 35 Fed. Reg. 9002 (1970).
106. Comments from individual consumers in response to the November 7, 1975 notice of
rulemaking were supportive of the requirement of a written source of information apart from
the physician source. 44 Fed. Reg. 40,019 (1979). Proponents of the PPI program include: the
consumer consortium described supra note 102; individual consumers, some individual physi-
cians and pharmacists, see Fleckenstein, infra note 108; and the American Nurses Association,
see Letter from Anne Zimmerman (President ANA) to Paul Rogers (Chairman Health and
Environment Subcomm. of the Comm. on Interstate and Foreign Commerce), May 25, 1978
(commenting favorably on the consumer labeling provision of H.R. 11,611).
107. The CBS Television Network conducted an extensive study of consumer information
needs for prescription drugs. CBS ECONOMICS AND MARKETING DESIGN, CBS TELEVISION
NETWORK, CBS CONSUMER MODEL (1983) [hereinafter cited as CBS STUDY]. The study was
designed to provide concrete documentation of consumer attitudes and behavior regarding
prescription drugs in an effort to provide scientific, reliable information useful for the debate
on prescription drug advertising. Major areas of concern regarding prescription drug use were
identified by consumer groups assembled in three geographically distinct areas of the country.
A questionnaire was developed based on the areas identified by the groups, and a pretest was
given to evaluate the clarity, completeness and appropriateness of the questionnaire. A nation-
ally projectable sample of 1,233 households was given the questionnaire through personal in-
home interviews. All questions were randomly rotated to prevent ordering effects. The results
were only projectable to the eight million U.S. households who have used prescription drugs in
the past, as all households studied reported some experience with prescription drugs. The
study reported that the general public is marginally informed about prescripton drugs. Of
those 1233 households who answered the survey, 33% stated they were well informed about
prescription drugs, while 38% reported they were not well informed and 28% stated they were
somewhat informed. CBS STUDY, supra, at 21, table 16. Similarly, a study on health care
practices conducted by the Proprietary Association found I 1% of the survey respondents used
prescription drugs already in the home to treat their health problems. HARRY HELLER RE-
SEARCH CORP., HEALTH CARE PRACTICES AND PERCEPTIONS 15, figure 13 (1984).
108. Medical groups that generally opposed the FDA oral contraceptive labeling included
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that (1) consumer-directed labeling would interfere with the doctor-patient
relationship, (2) that it would so alarm patients that some may refuse neces-
sary drug treatment, and (3) that a PPI could not possibly supply all the
information necessary for the safe and effective use of prescription drugs.'9
3. Legislative Dissatisfaction-Attempts to Mandate PPI Requirements
As a result of consumer dissatisfaction with the learned intermediary rule,
several bills were introduced in Congress to require PPIs.' 1 o The Drug Reg-
ulation Reform Act of 1978111 was intended, inter alia, to revise the federal
law regarding all drugs for human use to ensure that such drugs are safe and
effective." 2 The bill would have mandated a patient labeling requirement
that included the use of PPIs. 11 3 One rationale for the requirement was that
the American Medical Association (AMA), the Association of American Physicians and Sur-
geons, the American College of Obstetrics and Gynecology, the American Society of Internal
Medicine, and the AMA Interspecialty Committee. See 35 Fed. Reg. 9001 (1970). Pharma-
ceutical manufacturers, speaking through the Pharmaceutical Manufacturers Association, Wy-
eth Laboratories, Syntex, Ortho, and Parke, Davis, opposed the concept of consumer-directed
labeling because they believed that drug information must be given on an individual basis by
the physician. See 35 Fed. Reg. 9002 (1970). Interestingly, a study of 205 individual physi-
cians and pharmacists showed that a majority of the respondents favored PPIs. See Flecken-
stein, Attitudes Toward the Patient Package Insert-A Survey of Physicians and Pharmacists, 11
DRUG INFORMATION J. 23, 25 (1977). Seventy-two percent of the physicians and sixty-six
percent of the pharmacists responded affirmatively when asked whether they favored the devel-
opment of the patient package insert. Id. The advantages of consumer-directed labeling per-
ceived by this group were a better informed patient population, better compliance with drug
regimens, and avoidance of drug interactions and adverse reactions. Id.
109. 35 Fed. Reg. 9001 (1970). Some physicians argued that consumer-directed labeling
would unnecessarily interfere with the exercise of their medical judgment, thereby intruding
upon the doctor-patient relationship. Id.
110. S.2755, 95th Cong., 2d Sess., § 151(c), 124 CONG. REC. 3896 (1978); H.R. 12980, 95th
Cong., 2d Sess., 124 CONG. REC. H3029 (1978) and its predecessors, H.R. 11611, 95th Cong.,
2d Sess., 124 CONG. REC. H2184 (1978); H.R. 8891, 95th Cong., § 85(a)(1), 1st Sess., 123
CONG. REC. H8778 (1977); H.R. 14289, 94th Cong., 2d Sess., 122 CONG. REC. 17,165 (1976).
111. The Drug Regulation Reform Act of 1978 was comprised of bills introduced by the
Senate and the House calling for comprehensive reform of the federal drug laws. See supra
note 110, infra notes 112-13 and accompanying text.
112. A sponsor of H.R. 11611, Representative Paul Rogers of Florida, stated that if imple-
mented, the Drug Regulation Reform Act would "bring . . . the benefits of promising new
drug therapies to the marketplace more rapidly . . . better inform . . . citizenry about the
proper use and intended effects of drugs . . . [and] result in much safer use of drugs than can
be the case today." Introductory statement of Paul Rogers, Drug Regulation Reform Act of
1978: Hearings on H.R. 11611 before the Subcomm. on Health and the Environment of the
House Comm. on Interstate and Foreign Commerce, 95th Cong., 2d Sess. 1 (1978).
113. Section 151(b)(2)(c) of H.R. 11611, supra note 10 states,
CONTENTS-Information labeling for patients for a drug product shall contain
the following information (1) Adequate directions for use, including-(A) the pur-
poses or indications for which the drug product is intended, (B) the proper method of
administration of the drug product, (C) precautions to be taken during the use of the
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better patient compliance with prescription drug therapy could be achieved
through more complete understanding and knowledge regarding prescrip-
tion drugs." 4 Also emphasized were the same arguments advanced in sup-
port of the FDA's PPI program." 5 The patient labeling provision of the
Act was supported by consumer groups and opposed by organized medicine
and the pharmaceutical industry." 6 The PPI requirement of the Act was a
small part of a larger effort to effect major changes in the federal drug law.
The legislation contained provisions altering aspects of the investigational
use of drugs,' the export of drugs," 8 drug promotion and education,"
l9
and the penalties involved for prohibited acts.' 2° Opposition to these other
provisions of the Act, in addition to opposition to the consumer labeling
provision, ultimately proved too strong to overcome.' 2 ' Consumer groups
and legislators were unable to muster the necessary political force to pass a
bill containing such fundamental changes in federal drug laws.' 22
drug product, and significant side effects and adverse reactions that may result from
the use of the drug product, as well as instructions for treating or obtaining treatment
for these effects and reactions, and (D) warnings against unsafe use of the drug prod-
uct. (2) The proper storage and handling of the drug product. (3) Any other infor-
mation the Secretary finds necessary to protect the public health or to promote the
safe and effective use of the drug product by patients.
Drug Regulation Reform Act of 1978, Hearings on H.R. 11611 Before the Subcomm. on Health
and the Environment of the House Comm. on Interstate and Foreign Commerce, 95th Cong., 2d
Sess. 142-43 (1978).
114. Several studies were cited that demonstrated the relationship between increased
knowledge of prescription drugs and compliance with the drug treatment plan. Madden, Eval-
uation of Outpatient Pharmacy Patient Counseling, 13 J. AM. PHARMACEUTICAL A. 437
(1973); Colcher, Penicillin Treatment of Streptoccal Pharyngitis: A Comparison of Schedules
and the Role of Specific Counseling, 222 J.A.M.A. 657 (1972); see also Marston, Compliance
with Medical Regimens: A Review of the Literature, 19 NURSING RESEARCH 312 (1970).
115. See supra notes 97-102 and accompanying text.
116. See supra notes 106, 108 and accompanying text. Not surprisingly, the interested
parties lined the same side of the fence for debate on the Act as they did for the original PPI
debate. The American Association for Retired Persons, the National Consumers League, and
the American Nurses Association, all read statements favorable to the labeling requirements
into the record during the hearings on H.R. 11611. The American Pharmaceutical Manufac-
turers Association, the American Society of Internal Medicine, the AMA, the National Asso-
ciation of Retail Druggists and others spoke out against the labeling provisions.
117. Drug Regulation Reform Act of 1978: Hearings on H.R. 11611 Before the Subcomm.
on Health and the Environment of the House Comm. on Interstate and Foreign Commerce, 95th
Cong., 2d Sess. §§ 125-133 at 92-121 (1978).
118. Id. §§ 134-136, at 122-27.
119. Id. §§ 161-170, at 158-80.
120. Id. §§ 146-150, at 130-40.
121. Telephone interview with John McLaughlin, Counsel, House Subcomm. on Health
and Environment (Sept. 14, 1984).
122. Id.
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II. CONSUMER-DIRECTED PRESCRIPTION DRUG INFORMATION: Two
DECADES OF ABORTED STRATEGIES
Although the learned intermediary rule continues to be followed in most
American jurisdictions, 123 there is growing consumer interest in abandoning
the single-source system in favor of consumer-directed prescription drug in-
formation. The problems of the single-source informational system persist
despite attempts over the past twenty years to supplement drug information
provided by physicians.
The judicial response to the learned intermediary problem has been to
develop exceptions to the learned intermediary rule on a case-by-case basis.
Generally, courts have imposed a duty to warn the consumer only where no
physician is present to act as a learned intermediary. 24 In addition, the
manufacturer must have been able to anticipate the absence of a physician-
intermediary at the time when the drug was administered. 125 The advan-
tages of a case-by-case approach are threefold. First, the approach results in
a judicial remedy based only on a narrow set of facts. Broad, sweeping
changes in what has been a well-settled area of law are thereby avoided.
Second, if the rule is uniformly applied, the approach is predictable. Manu-
facturers, physicians and patients can base their actions on the outcomes of
prior controversies. Finally, any liability imposed through case-by-case de-
terminations is easily anticipated by manufacturers if courts adhere to
precedent.
The disadvantage of the case-by-case approach, however, is that the nu-
merous problems associated with the single-source informational system de-
mand a comprehensive solution that cannot be satisfied through case-by-case
adjudication. The present system does not effectively promote the safe use of
prescription drugs. It simply provides an after-the-fact remedy for the in-
jured consumer. In addition, it is costly and inefficient to litigate each con-
troversy on a case-by-case basis. Finally, any information requirements that
were imposed by case-by-case adjudication would lack uniformity. Compre-
hensive change in so settled an area of law and public policy is better under-
taken legislatively or administratively.
The narrow approach favored by the courts is illustrated in Bacardi v.
Holzman.126 In Bacardi, no effective doctor-patient relationship existed be-
cause the patient saw many different physicians over an extended period of
123. See supra notes 42, 63 and accompanying text.
124. See supra note 84 and accompanying text.
125. Davis, 399 F.2d at 131.
126. 182 N.J. Super. 422, 442 A.2d 617 (1981).
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time.' 27 For all practical purposes, there was no individualized weighing of
the risks and benefits of the drug therapy after the initial diagnosis and pre-
scription. In the words of the Reyes court, "the very justification for the
prescription drug exception evaporate[d]."' 2 s The drug injury might possi-
bly have been avoided had the patient been aware of the dangers presented
by long-term treatment with the drug so that the history of extended use
could be adequately stressed to subsequent physicians. Yet, the court specif-
ically refused to extend the learned intermediary exceptions beyond the mass
immunization cases, where an exception to the rule was dictated by the fact
that a physician did not administer the drug.'2 9 A similarly harsh result can
be imagined in the many cases today where a physician prescribes the drug
by telephone. Although technically the physician has prescribed the drug,
the patient does not receive the benefits of a learned intermediary because
there is no meaningful doctor-patient relationship.
Case-by-case adjudication of the single-source problem lacks uniformity
because each court must determine whether the manufacturer has a duty to
the consumer on the basis of the individual facts of each case., ° Under the
Dunn v. Lederle case, for example, a manufacturer is required to warn the
consumer where no physician is present. 13' The Dunn court, however, failed
to fashion a concrete standard, leaving the details of applying the rule of law
open for future determination.
The most serious inadequacy of the case-by-case approach to the single-
source problem is that it fails to provide a method for improving the safety
of prescription drug use. In the learned intermediary decisions, courts have
focused on whether a manufacturer should be held liable for drug-induced
injuries when the physician has been adequately warned. The outcomes of
the learned intermediary cases demonstrate that the consumer has no legal
right to receive information about prescription drugs from the manufac-
turer. 132 A manufacturer's duty to reach the consumer is discharged by
warning the physician where the physician is present to balance the risks and
benefits of drug therapy. 13 3 The learned intermediary rule was derived from
an analysis of the physician's unique role in the distribution of the manufac-
127. Id. at 425, 442 A.2d at 619.
128. 498 F.2d at 1276.
129. 182 N.J. Super. at 427, 442 A.2d at 620.
130. Smith, 273 N.W.2d at 479. The Smith court stated that "[dietermination of whether
[the duty to warn the consumer] has been breached in the context of a negligence claim neces-
sitates that the warnings given be examined as to their reasonableness under the circum-
stances." Id.
131. Dunn, 121 Mich. App. 73, 79 n.ll, 328 N.W.2d at 579 n.1l.
132. See supra note 3 and accompanying text.
133. Id.
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turer's product, and it adequately resolves the liability issue in a prescription
drug injury case. Resolving apportionment of liability, however, does not
assure that prescription drug use will be safer in the future. While the judici-
ary is rightly concerned with the liability issue in the short-run, it also
should be concerned with the improvement of prescription drug use in the
long-run. The judiciary has never attempted to address this issue because it
is not a problem that is easily framed by an individual controversy.
The learned intermediary rule has contributed to drug manufacturers' un-
willingness to provide consumer-directed labeling. From an economic
standpoint, there is no reason to provide consumers with information where
no liability is imposed. Additionally, judicial language suggesting that con-
sumer-directed labeling is not effective to communicate warnings to consum-
ers further dampens manufacturer incentive to provide such information.' 
34
Although the learned intermediary rule may be adequate for determining
liability, it exacerbates the single-source problem by discouraging manufac-
turers from providing consumer-directed labeling.
The administrative approach, manifested by the FDA's PPI program, ad-
dresses the broader issue of prescription drug safety. An administrative
mandate requiring consumer-directed prescription drug labeling takes the
learned intermediary rule one step further. The physician's primary respon-
sibility in receiving drug information is not challenged by the concept of the
PPI.' 35 The administrative approach requires that the manufacturer reach
consumers as well as physicians to effectively decrease the dangers of pre-
scription drug use.' 36 Thus, consumer-directed labeling would neither re-
place the physician's responsibility to communicate warnings nor replace the
learned intermediary system of apportioning liability.
The administrative approach, characterized by the FDA's PPI program,
provides benefits similar to the legislative initiative in that a regulatory re-
quirement could be well planned and uniform in effect. Certainty would be
given to adversarial disputes regarding a manufacturer's duty to give infor-
mation to the consumer. The FDA initiated a far-reaching effort to gather
public comment from interested parties prior to its 1979 PPI rulemaking. 37
134. See supra notes 6, 18 and accompanying text.
135. See infra notes 149-52 and accompanying text.
136. Id.
137. The Patient Prescription Drug Labeling Project was initiated by the FDA, in part to
solicit input regarding the PPI program. The project included numerous meetings with physi-
cian, pharmacy and consumer advocacy groups. In addition, the project included a national
symposium held in 1975 to solicit the viewpoints of various interested parties. See Special
Supplement THE DRUG INFORMATION J. (1977) (symposium proceedings). In addition, the
FDA received 1,000 comments regarding the PPI program in response to the 1975 notice of
rulemaking. 40 Fed. Reg. 52,075 (1975).
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Nevertheless, an administrative agency must be responsive to the political
climate in which its regulations are promulgated, and a PPI requirement
necessitates an atmosphere favorable to the regulation of the prescription
drug manufacturer. Thus, in light of the changes in policy resulting in re-
duced business regulation fostered by the Reagan administration, final regu-
lations establishing a PPI requirement for all prescription drugs (to be
applied to ten drugs in an initial implementation program) were withdrawn
after promulgation but before implementation.
13 8
III. CONSUMER-DIRECTED PRESCRIPTION DRUG INFORMATION-THE
BEST ANSWER TO AN ONGOING PROBLEM
The problems that have emerged from the use of a single-source informa-
tional system flow from the fact that such a system does not promote the
safest possible use of prescription drugs. The single-source system depends
upon the physician or a substitute to educate the consumer about prescrip-
tion drugs. The physician, however, does not give drug information to pa-
tients under circumstances which are optimal for patient learning to
occur. 13 9 Moreover, where there is no physician to fulfill the teaching func-
tion, there is no formal method through which the consumer may obtain the
information. Consumers may acquire access to a package insert, containing
information intended for the health care practitioner through the Physician's
Desk Reference (PDR), which is available commercially to the public."
Technical medical knowledge, however, is a prerequisite to proper under-
standing and use of the package insert. The package insert contains detailed
information about a prescription drug's chemical makeup, pharmacological
action, and physiological effects."' It sets forth the onset and duration of
138. 47 Fed. Reg. 39,147 (1982).
139. See supra note 9 and accompanying text.
140. The CBS STUDY, supra note 107, found that 35% of all the households studied, or 27
million households, used the PDR for information regarding prescription drugs and 18%, or
14 million, actually owned a PDR for similar use. CBS STUDY, supra note 107, at 8, table 3.
For a discussion of the consequences of consumer reliance on the package insert for prescrip-
tion drug information, see text.
141. Compare the following excerpt from the PDR providing technical information on pro-
poxyphene (trade name "Darvon") with the proposed PPI on propoxyphene, supra note 102.
Description: Darvon (propoxphyene hydrocloride, Lilly) is an odorless white
crystalline powder with a bitter taste. It is freely soluble in water. Chemically, it is
alpha(+ )4(Dimethylamino)3methyl I, 2diphenyl2butanol Propionate Hydrocloride.
Clinical Pharmacology: Propoxyphene is a centrally acting narcotic analgesic
agent. Equimolar doses of propoxyphene hydrocloride or napsylate provide similar
plasma concentrations. Following administration of 65, 130, or 195 mg of propox-
yphene hydrochloride, the bioavailability of propoxyphene is equivalent to that of
100, 200, or 300 mg respectively of propoxyphene napsylate. Peak plasma concentra-
tions of propoxyphene are reached in two to two and one-half hours. After a 65-mg
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pharmacologic action, where the drug is broken down and excreted, and
possible adverse interactions with other drugs. Moreover, it details any ad-
verse effects of the drugs reported, no matter how rare. The package insert
also provides guidelines for indications and dosages, although a physician
may use a different dosage according to the specific needs of the patient.
Information reaching consumers in this manner does not promote the safe
use of prescription drugs, because much of the technical information is sus-
ceptible to misinterpretation by the consumer. For example, a package in-
sert may state that a certain antibiotic drug is contraindicated for persons
with kidney disease. The reason for such a warning-that the drug is ex-
creted mainly by the kidney, and that a person with compromised kidney
function would not efficiently excrete the drug-may not be noted by the
package insert. A physician, however, when faced with the necessity of pre-
scribing this particular antibiotic, may safely have prescribed a lower dosage
oral dose of propoxyphene hydrochloride, peak plasma levels of 0.05 to 0.1 mcg/ml
are achieved. Repeated doses of propoxyphene at six-hour intervals lead to increas-
ing plasma concentrations with a plateau after the ninth dose at 48 hours.
Propoxyphene is metabolized in the liver to yield norpropoxyphene. Propox-
yphene has a half-life of six to 12 hours, whereas that of norpropoxpyhene is 30 to 36
hours.
Drug Dependence-Propoxyphene, when taken in higher-than-recommended
doses over long periods of time, can produce drug dependence characterized by
psychic dependence and, less frequently, physical dependence and tolerance. Pro-
poxyphene will only partially suppress the withdrawal syndrome in individuals phys-
ically dependent on morphine or other narcotics. The abuse liability of
propoxyphene is qualitatively similar to that of codeine although quantitatively less,
and propoxyphene should be prescribed with the same degree of caution appropriate
to the use of codeine.
Usage in Ambulatory Patients-Propoxyphene may impair the mental and/or
physical abilities required for the performance of potentially hazardous tasks, such as
driving a car or operating machinery. The patient should be cautioned accordingly.
Precautions: General Precautions-Kidney disease, often irreversible, has been
noted with doses of phenacetin of I gm or more per day taken for one to three years
and with total ingestion of 2 kg or more. It is not known whether prolonged inges-
tion of doses of phenacetin lower than I gm per day might also result in kidney
disease.
Salicylates should be used with extreme caution in the presence of peptic ulcer or
coagulation abnormalities.
Drug Interactions-The C.N.S.-depressant effect of propoxyphene is additive with
that of other C.N.S. depressants, including alcohol. Salicylates may enhance the ef-
fect of anticoagulants and inhibit the uricosuric effect of uricosuric agents.
Usage in Pregnancy-Safe use in pregnancy has not been established relative to
possible adverse effects on fetal development. Instances of withdrawal symptions in
the neonate have been reported following usage during pregnancy. Therefore, pro-
poxyphene should not be used in pregnant women unless, in the judgment of the
physician, the potential benefits outweigh the possible hazards.
PHYSICIAN'S DESK REFERENCE 1123-25 (38th ed. 1984).
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of the drug to compensate for inefficient excretion. In such an example, the
physician would be aware of other factors which negate the apparent warn-
ing of the package insert.
A consumer who has neither sufficient information to weigh the risks and
benefits of a prescription drug nor a learned intermediary to do so for him,
risks exposure to an unreasonably dangerous product. The learned interme-
diary rule gives physicians the sole authority to decide what information
should be shared with the patient and what should be withheld. In today's
medically conscious society, however, the patient should be regarded as a
consumer of a product. The consumer should be an active participant in the
plan of care, rather than a passive recipient of whatever information the phy-
sician deems best. Detailed information tailored to the needs of the con-
sumer must be available so that the risks and benefits of a proposed drug
therapy can be properly weighed.' 42 If the consumer/patient took a more
active role in his/her care, the burden would no longer rest solely with the
physician to decide what the consumer should know about prescription
drugs.
Although the problems of the single-source system may be clear,' 4 3 the
solutions to those problems are not so evident. Pharmaceutical manufactur-
ers and physician groups maintain that providing prescription drug informa-
tion directly to consumers would create difficulties without improving on the
present system.' They raise several arguments critical of consumer-di-
142. Morris, Patient Package Inserts A New Toolfor Patient Education, Drug Regulation
Reform Act of 1978: Hearings on H.R. 11611 before the Subcomm. on Health and the Envi-
ronment of the House Committee on Interstate and Foreign Commerce 95th Cong., 2d Sess.
1189 (1978).
143. In discussing H.R. 11611 and the Drug Regulation Reform Act in general, Represen-
tative Rogers stated that although he had received numerous and substantial criticism of the
bill itself,
not one person who has discussed the bill with me . . . has suggested that the
existing drug law is appropriate or that the status quo should be maintained. I think
there is all but unanimous agreement that the existing law is archaic and is badly in
need of revision.
Drug Regulation Reform Act of 1978." Hearings on H.R. 11611 before the Subcomm. on Health
and the Environment of the House Comm. on Interstate and Foreign Commerce, 95th Cong., 2d
Sess. (1978) (statement of Rep. Rogers).
144. Organized medicine, represented by various associational groups, opposed the FDA
PPI program from its inception in 1970. 35 Fed. Reg. 9001 (1970). See also 45 Fed. Reg.
60,756 (1980). The American Medical Association has stated:
As to information pertaining to side effects, contraindications, adverse effects, and
purposes or indications of a drug, there should be no requirement that all such infor-
mation be in patient labeling for all drugs. Should requirements or regulations man-
dating the inclusion of such information in patient labeling for all prescription drugs
be promulgated, the public interests would not be served. Interference in the physi-
cian/patient relationship would result, and patients' medical needs would not be met,
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rected information. The arguments, however, are outweighed by the positive
gains anticipated from, and actually demonstrated by the use of a multi-
source informational system. The evidence suggests that society has much
to gain from relieving physicians of some of the burdens of imparting pre-
scription drug information and diversifying the sources from which consum-
ers may learn about their drugs.
A. The "Self-Medication" Argument
The basic premise of the learned intermediary rule is that the physician
must be free to exercise independent judgment in deciding what facts to dis-
close to the consumer. '45 Traditionally, the consumer had to rely upon the
physician's background and skill in evaluating the risks and benefits of a
prescription drug. 146 One rationale for this practice is that information di-
rected toward the consumer could result in the dangerous practices of self-
diagnosis and attempted self-medication.' 47 Therefore, consumer-directed
labeling should be limited to non-prescription medications. This view repre-
sents an approach to treatment with prescription drugs that may be out-
dated. Statistics show that the wants and needs to take a more active role in
public medical care.'14
Self-diagnosis and self-medication are not goals of consumer-directed la-
beling. Consumer labeling is designed and intended only to reinforce and
remind the consumer of information which is ideally provided by a physi-
cian. 149 Former FDA Commissioner Kennedy has stated that the labeling
in that a patient receiving such information may be uncertain as to the need for
benefits of a drug as part of a prescribed therapeutic regimen. Consequent unwilling-
ness to accept the prescription of a physician would be detrimental in terms of public
health.
See Smith, Patient Package Inserts and the U.S. Food & Drug Administration-Where Do We
Stand at the Moment?, 11 DRUG INFORMATION J. 30, 31 (1977).
145. See, e.g., Terhune v. A.H. Robins Co., 90 Wash. 2d 9, 14, 577 P.2d 975, 978 (1978).
146. Id.
147. 43 Fed. Reg. 4220 (1978). In its statement before the Subcommittee on Health and
Environment during the hearings on H.R. 11611, the AMA stated
Medical information regarding drug therapy prescribed for the patient originates
with the physician, who is in the best position to determine the scope and complexity
of information that would be appropriate for the individual patient. Mandatory de-
tailed patient labeling . . . could discourage proper patient use of a drug and en-
courage inappropriate self-medication by patients for themselves and their families.
Additional Comments Accompanying the Statement of the AMA, The Drug Regulation Reform
Act of 1978, reprinted in Drug Regulation Reform Act of 1978: Hearings on H.R. 11,611
Before the Subcomm. on Health and the Environment of the House Comm. on Interstate and
Foreign Commerce, 95th Cong., 2d Sess. 2633 (1978).
148. See supra notes 100, 107, 114 and accompanying text.
149. 42 Fed. Reg. 37,637 (1977).
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requirements are not intended to supersede the physician's responsibility or
judgment in providing drug information to the consumer. 5' In fact, oral
contraceptive labeling directs the consumer to consult with a physician re-
garding any pertinent medical history the user may have.151 Recognizing
the primary role of a physician in selecting and disseminating information
regarding prescription drugs, the FDA also asserted that warnings directly
to the consumer may result in "improved patient compliance with physi-
cian's directions . . . self-monitoring of adverse effects, and a corresponding
decrease in drug-induced injury." '152
B. Paternalism Lives: The "Too Technical" Argument
Another criticism of consumer-directed labeling is that consumers do not
have the requisite medical knowledge, education, or experience to properly
evaluate complex and technical warnings." 3 In addition, consumer warn-
ings might dissuade consumers from consenting to necessary therapy. 15
150. See, e.g., 42 Fed. Reg. 37,636 (1977). In the final rules requiring PPIs for all es-
trogenic drug products, effective September 20, 1977, former Commissioner Kennedy stated:
The Commissioner does not agree that the requirement for patient labeling inter-
feres with the physician/patient relationship or infringes on the practice of medicine.
Indeed, by directing the patient to consult with her physician the labeling require-
ment explicity recognizes the primary responsibility of the prescribing physician to
convey to the patient, [sic] information regarding prescribed drugs. This regulation,
therefore, is not intended to preempt the physician's responsibility, nor will it have
that effect. Rather, in situations where physicians are conscientious in describing the
relative benefits and risks of these drugs with their patients, the patient labeling will
simply reinforce what the physician has explained to the patient and serve as a writ-
ten reminder that can be referred to by the patient during the course of therapy.
42 Fed. Reg. 37,637 (1977).
151. 21 C.F.R. § 310.501(a)(2)(ii) (1978). Section 310.501(a)(2)(ii) directs that patient la-
beling for oral contraceptives must contain "[a] statement of the specific items of history to be
told the physician that would lead the physician not to prescribe oral contraceptives." 21
C.F.R. § 310.501(a)(2)(ii) (1978).
152. 43 Fed. Reg. 4214 (1978).
153. See supra note 6 and accompanying text.
154. Id. The National Association of Chain Drug Stores (NACDS), in its statement before
the subcommittee regarding H.R. 11611 stated:
[B]ecause [the PPI information currently required under FDA regulations] is so
flagrantly slanted toward the undesirable aspects of therapy, it is our firm belief that
under a comprehensive package insert program, a vast number of patients who re-
ceive this alarming kind of information will be frightened from taking their medica-
tions. . . . [I]f patient noncompliance increases, greater numbers of individuals
might develop more serious illnesses, which could lead to higher health care costs
Drug Regulation Reform Act of 1978: Hearings on H.R. 11611 Before the Subcomm. on Health
and Environment of the House Comm. on Interstate and Foreign Commerce, 95th Cong., 2d
Sess. 2665 (1978) (statement of Sheldon W. Fantle, Director, National Ass'n of Chain Drug
Stores). The NACDS prediction is contradicted by studies showing that increased consumer
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This argument belies a misunderstanding of the objectives of consumer-di-
rected labeling. The public policy objective is to enhance the safety of pre-
scription drugs by allowing consumers to make informed decisions regarding
their use.' 55 For example, the FDA regulations do not require the manufac-
turer to disclose information to consumers that is identical to that dispensed
to physicians, nor does it require complex or technical warnings.' 56 Manu-
facturers have shown it is possible to effectively provide information in lay
terms through their directions and package inserts for nonprescription drugs
as well as through the pamphlets required by the FDA for oral
contraceptives. 1
57
In response to the arguments that consumer-directed labeling might result
in refusal of treatment, it should be noted that the necessity of administering
the drug and the reasons for its use have a bearing on whether consumer-
directed information increases the safe use of a prescription drug. Where the
prescription drug is used to treat an illness, the warning may serve to dis-
suade the consumer from using the drug even where the consumer is fully
informed of the necessity and therapeutic value of its use. Nevertheless, the
consumer's decision should be respected.' 58 Withholding the warning infor-
mation in an attempt to ensure that the consumer will consent to the therapy
that the physician has judged to be necessary ignores the principles of in-
formed consent. Rather, the physician should give the consumer the respon-
sibility of deciding whether to undergo the suggested treatment by
communicating the information and reasoning which lead the physician to
recommend the drug therapy.
The refusal-of-treatment argument is especially inappropriate where the
use of the drug is considered elective. Presumably, the consumer will be less
willing to incur the risks of adverse effects in such a case because even small
risks may outweigh the benefits of elective drug use by a healthy consumer.
While the decision whether to use a drug to cure an illness must be made
knowledge leads to better compliance with therapeutic regimens. See Colcher, supra note 114,
at 657.
155. Terhune, 577 P.2d at 978.
156. 21 C.F.R. § 310.501(a)(1) (1978) (requiring the information to be in lay language).
157. Warnings and directions for use are printed in lay terms on all nonprescription drugs,
showing that the manufacturer is capable of communicating technical information to the con-
sumer. Although, by definition, nonprescription drugs are not as dangerous as prescription
drugs, many are nevertheless potent medicine with the potential to cripple or kill if used im-
properly. Nevertheless, manufacturers are able to translate complex technical information
into language allowing over-the counter use by a lay public. Moreover, manufacturers have
been supplying patient-oriented information with favorable results through oral contraception
pamphlets since 1970.
158. See generally Note, Restructuring Informed Consent.: Legal Therapy for the Doctor-
Patient Relationship, 79 YALE L.J. 1533 (1970).
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with an understanding of the consequences of no treatment, where the use of
the drug is elective, the consumer need only weigh the desired results of the
drug against the possible adverse effects.
For example, where the elective drug is an oral contraceptive, the physi-
cian may be in the best position to judge whether the risk of a stroke out-
weighs the benefit of the drug for most patients.' 59 This judgment will affect
the doctor's willingness to prescribe the drug. Although the physician may
be assured by professional analysis that the risks do not outweigh the bene-
fits, the doctor is not in the best position to decide whether that consumer
would elect another form of birth control in light of the attendant risks.
Thus, under the single-source system, the consumer's right to choose could
be preempted if, in the physician's judgment, it is not necessary to communi-
cate all the factual information regarding the drug. A consumer cannot ex-
ercise an effective choice where a physician decides not to disclose a
particular risk because of a belief that the risk does not outweigh the benefit
of the drug. Further, where the drug use is considered elective, consumer-
directed labeling would facilitate the safe use of prescription drugs because a
healthy consumer is less likely to be under the close supervision of a physi-
cian. " Consumer information would reinforce and remind the consumer of
factors necessary for the safe use of the drug.
C. The "Too Much Liability" Argument
Consumer-directed labeling has also been criticized as burdensome be-
cause it creates the possibility of additional manufacturer liability.' 6' The
feasibility of manufacturer warnings has been questioned because the con-
sumer normally does not receive the drug in the packaging released by the
manufacturer, nor does he have substantial contact with the manufac-
turer. 16 2 Pharmaceutical manufacturers argue that imposing the duty to
warn under these circumstances would be financially burdensome.' 63 The
FDA estimates, however, that the PPI program would add only 1.5 cents to
the cost of a prescription. 6' This amount is inconsequential in light of the
159. See supra note 6 and accompanying text.
160. Consumers Union, Petition to the FDA to Require More Adequate Patient Labeling
of Prescription Drugs, 24-29 (1975).
161. See 42 Fed. Reg. 37,637 (1977).
162. See Davis, 399 F.2d at 130; Terhune, 577 P.2d at 978.
163. 42 Fed. Reg. 37,637 (1977).
164. Eve Bargmann, Public Citizen Health Research Group to the FDA on FDA's Pro-
posed Revocation of the Patient Package Insert Program, (April 20, 1982) (Comments). Dr.
Bargmann submitted a forceful and persuasive comment to the FDA upon the announcement
of the agency's intention to revoke the PPI requirements. Citing a study of the effects of PPIs,
Dr. Bargmann pointed out that PPIs reach patients with potentially lifesaving information,
1984]
Catholic University Law Review
fact that in 1983, the average cost of a prescription was $11.20.165 Consider-
ing that former FDA Commissioner Kennedy estimated that drug manufac-
turers spend approximately $4,000 yearly per practicing physician to
promote prescription drugs,166 it is unlikely that a consumer labeling re-
quirement would prove burdensome. In addition, the inserts mandated by
the FDA are similar in nature to those inserts already distributed to physi-
cians. Manufacturers, therefore, need only include information pamphlets
with the bulk drugs.
167
With regard to the potential increase in manufacturer liability, a manufac-
turer could incur additional liability under a strict liability theory or negli-
gence per se if its consumer-directed labeling failed to reach the consumer or
if the labeling was inadequate. 16' The manufacturers' legal duty to warn
remains physician-oriented, however, and it is unlikely that the law will
change to create greater liability where the manufacturer adequately warned
the physician. 169 Consumer-directed labeling would supplement drug infor-
mation given by the physician. Even with consumer-directed labeling, the
primary responsibility for informing consumers about their prescriptions
would remain with physicians. In this manner, the liability for failure to
warn could be discharged by warning the physician of possible dangers in-
herent in the drug. Moreover, liability for failure to warn is based on a
reasonableness standard, not on strict liability. 170 Manufacturers who prop-
and would cost only two cents each to print. Comments, supra at 2 (citing Fisher, Package
Patient Inserts: Dogma and Data, 17 PSYCHOPHARMACOLOGY BULL. 173-74 (1981)). Dr.
Bargmann asked, "[i]s FDA willing to cancel a cost-effective, potentially life-saving program
with strong public support, simply because industry and trade groups do not like it?" Com-
ments, supra at 2.
165. 50 PHARMACY TIMES 30 (1984). This figure was calculated by the National Prescrip-
tion Drug Audit, using the 200 most frequently prescribed drugs in 1983.
166. Kennedy, supra note 102 at 387.
167. 21 C.F.R. § 310.501 (a)(6)(ii) (1984). See also Gardner, Increasing Patient Awareness
In Drug Therapy. Ramifications of a Patient Package Insert Requirement, 66 GEO. L.J. 837,
858 (1978).
168. See Lukaszewicz v. Ortho Pharmaceutical Corp., 510 F. Supp. 961 (E.D. Wis. 1981)
(failure to provide a PPI as required by FDA regulations held to be negligence per se).
169. See supra, note 3 and accompanying text.
170. See Brochu v. Ortho Pharmaceutical Corp., 642 F.2d 652 (1st Cir. 1981) (reasonable
warning gives a fair indication of the dangers involved and warns with the intensity demanded
by the extent of the risk); Mahr v. G. D. Searle, 28 11. Dec. 624, 390 N.E.2d 1214 (1979)
(adequacy of warning based on a reasonableness standard). The reasonableness standard for
prescription drug warnings has been reaffirmed even in light of the holding in Beshada v.
Johns-Manville Prod. Corp., 90 N.J. 191, 447 A.2d 539 (1982). Beshada held that ignorance
of the danger of asbestos exposure was not a defense to an action by workers suffering from
asbestos-related illnesses. Id. at 209, 447 A.2d at 549. The underlying rationale for the hold-
ing was that manufacturers of defective products could best absorb the costs of injuries result-
ing from the use of those products. Id. at 205, 447 A.2d at 547. Beshada, however, was not
followed in a subsequent case involving prescription drugs because "the almost absolute liabil-
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erly warn the prescribing physician and complete their statutory obligation
by including a PPI with the drug would be acting reasonably to fulfill their
obligation to warn. Former Commissioner Kennedy responded to the in-
creased liability argument by stating that effective use of information by con-
sumers could potentially decrease manufacturer liability by improving
patient compliance with drug treatments, thereby reducing drug-induced
injuries. 171
Consumer-directed manufacturer warnings may also be criticized based
on consumer disregard of important warnings because of the desensitization
caused by indiscriminate warnings. FDA statements regarding the oral con-
traceptive regulations suggest, however, that only serious warnings need be
included in the consumer information.' 72 In addition, this solution could be
followed in other areas. If the warning is sufficiently important to be in-
cluded in physician-directed labeling, there is little reason to believe the con-
sumer would not be served equally by the same information in lay terms.
Another possible adverse effect of consumer-directed labeling is the oppor-
tunity for manufacturer advertising through the labeling. This problem has
been addressed by the courts in a case where over-promotion of a drug to
physicians resulted in dilution of an otherwise adequate warning, leading to
manufacturer liability.' 73 Liability has been imposed on the manufacturer
where the warning written on the package insert was weakened by vigorous
promotion of the drug by detailmen.' 74 Inappropriate consumer-directed la-
beling could be handled similarly. Some drug manufacturers have, in fact,
initiated consumer-directed marketing through drug advertisements. 175
Although former FDA Commissioner Arthur Hayes expressed cautious ap-
proval so long as the advertisements were truthful,' 76 the FDA currently is
ity . . . of the Beshada approach would chill if not smother the research, development, pro-
duction and marketing of new or experimental drugs necessary to alleviate or cure the ills to
which we are all subject." Feldman v. Lederle Laboratories, 189 N.J. Super. 424, 428-29, 460
A.2d 203, 205 (1983).
171. 42 Fed. Reg. 37,637 (1977).
172. See 43 Fed. Reg. 4218 (1978) (stating that no warning regarding the incidence of
candidiasis, a vaginal yeast infection, was necessary because the incidence was neither common
nor serious).
173. See Stevens v. Parke, Davis & Co., 9 Cal.3d 51, 67, 507 P.2d 653, 662, 107 Cal. Rptr.
45, 54 (1973); Incollingo v. Ewing, 444 Pa. 263, 289, 282 A.2d 206, 220 (1971); Love v. Wolf,
226 C.A.2d 378, 38 Cal. Rptr. 183 (1964).
174. Id.
175. In 1981 the Boots Company advertised Rufen, its brand name form of the anti-inflam-
matory analgesic ibuprofen. In addition, a prescription drug advertisment for Zovirax, a drug
for herpes, was used by Peoples Drug Stores in 1982. Buc, Current Regulatory Issues in Mar-
keting Prescription Drugs. Comparative Claims and Advertising to Consumers, 37 FOOD DRUG
CosM. L.J. 402, 407 (1982).
176. Buc, supra note 175, at 407.
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evaluating its position on the issue.177 Although prescription drug advertis-
ing is not illegal, the FDA called a moratorium on it in 1983 in order to
collect more information on the subject.'
7
1
IV. ADDITIONAL METHODS FOR PROVIDING PRESCRIPTION DRUG
INFORMATION TO CONSUMERS
An administratively mandated program designed to ensure consumer-di-
rected information is the preferred method of improving the single-source
system. The information provided would be accurate and the distribution of
information uniform.' 7 9 Perhaps due to the lack of an administrative man-
date, however, other methods exist that haphazardly provide information to
the public in response to specific situations. For example, at least one pre-
scription drug manufacturer, Eli Lilly and Company, has developed Patient
Information Sheets for certain prescription drugs.'O Physicians may obtain
the Patient Information Sheets, along with illustrations of dosage forms and
prescription vial stickers, from the manufacturer for use as an adjunct to
physician teaching.''
In addition, the FDA has published consumer-directed warnings, as in a
poem designed to warn consumers about drug-induced sensitivity to sun-
shine.'" 2 The poem was part of a public service campaign designed to in-
crease consumer awareness about prescription drugs and to encourage
consumers to question their physicians about them.
177. A moratorium on direct-to-consumer advertising for prescription drugs was requested
by former Commissioner Arthur Hull Hayes, M.D. in February, 1983. The purpose of this
voluntary moratorium was to allow the FDA to conduct public forums and sponsor research
to obtain the public's view of prescription drug advertising. Address by Arthur Hull Hayes,
Jr., M.D., Pharmaceutical Advertising Council Annual Meeting (Feb. 17, 1983).
178. Id.
179. See, e.g., supra note 102 and accompanying text.
180. Patient Information Sheets containing detailed consumer information are available for
"Darvon", PHYSICIAN'S DESK REFERENCE 1125 (38th ed. 1984), and "Humulin", human
insulin. Id. at 1135-38.
181. PHYSICIAN'S DESK REFERENCE at 1125.
182. 18 FDA Cons. 48-49 (June, 1984). The poem appeared as part of a layout in FDA
Consumer, which included the picture of a sunburned man. The text read:
HE GOT THE PRESCRIPTION,
THEN HE GOT A BAD SUNBURN
THE TWO WERE CONNECTED.
This is the tale of a man who loved fun.
He took tetracycline, then lay in the sun.
But to his dismay it was then he did learn
That some drugs plus sunshine can lead to a burn.
Many people are not aware that some prescription drugs make them especially
sensitive to the ultraviolet rays from the sun and sunlamps. This reaction is called
"photosensitivity". Such a reaction is known as a side effect, or adverse reaction.
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Another possible source of drug information is prescription drug advertis-
ing to the consumer. Prescription drug advertising is a controversial subject
and its effects on the public and the drug industry are currently being stud-
ied by the FDA and other interested parties.'1 3 Whether such advertising
would provide truthful, reliable information to consumers may depend upon
the extent of both FDA regulation and manufacturer responsibility.
Private publications present another source for the communication of
drug information to consumers. Publications currently exist for both pre-
scription and non-prescription drugs which discuss directions for use, side
effects, and warnings. "4 This source of information requires a high level of
consumer motivation. It would be effective only for those consumers who
bought and read the book.
V. CONCLUSION
A multi source system for the communication of prescription drug infor-
mation to consumers is necessary and desirable to promote the safe use of
prescription drugs. The content and manner in which the information is
communicated should be regulated by the FDA, due to the greater uniform-
ity, certainty, and full evaluation prior to rulemaking that this approach
would provide. Although the need for multiple sources of consumer infor-
Prescription drugs can often cause unwanted side effects (nonprescription drugs can,
too).
The widely used antibiotic tetracycline is just one of the drugs that can
contribute to an unexpected sunburn. Some high blood pressure drugs and some
tranquilizers can do the same thing. When you get any prescription, be sure you
know-
The name of the drug
Its purpose- what conditions does it treat?
How and when to take the drug-and when to stop taking it
What food, drinks and other drugs to avoid while taking it
What side effects may result-are they serious, short-term,
long-term, etc.?
If you have questions about your prescription, ask your doctor or pharmacist.
18 FDA Cons. 49 (June 1984).
183. The CBS STUDY, supra note 107, was undertaken in order to provide concrete infor-
mation to the prescription drug advertising debates.
184. Currently there are numerous publications on the market that contain consumer in-
formation about prescription drugs. Written by physicians, laypersons, and the government,
these publications range from the very detailed and scientific to subjective consideration of the
topic. For information on prescription drugs, see R. BURACK, THE NEW HANDBOOK OF
PRESCRIPTION DRUGS (1980); D. MASON, PHARMACEUTICAL DICTIONARY AND REFER-
ENCE FOR PRESCRIPTION DRUGS (1981); E. STERN, PRESCRIPTION DRUGS AND THEIR SIDE
EFFECTS (4th ed. 1983); S. WOLFE, PILLS THAT DON'T WORK (1980). For information on
non-prescription drugs, see R. BENOWICz, NON-PRESCRIPTION DRUGS AND THEIR SIDE EF-
FECTS (1982); M. RUBINSTEIN, A DOCTOR'S GUIDE To NON-PRESCRIPTION DRUGS, (1977).
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mation has been articulated in Congress, by the FDA and by consumers, no
alternative system is in place today to supplement information consumers
receive from their physicians. Political opposition has hampered the efforts
of the legislature and the FDA. Judicial action regarding the problem has
only provided solutions on a case-by-case basis. Sources of prescription drug
information are available to the public, but they are sporadic in nature and
do not insure that the necessary information is consistently available. The
safe and effective use of prescription drugs will be compromised until an
organized multi-source drug information system is established.
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